Advances in Precision-based Nano Technology Targeting Neurological Disease
Join Vyripharm Biopharmaceuticals for a group of lectures surrounding the application of nanotheranostic technology in the evaluation of integrated medicine in neurological disease and cancer, as well as the role of the human endocannabinoid system in neuroinflammation, neurodegeneration and neuroelectrical pathology.
Those will be followed by discussions from others in the biosciences industry and a panel discussion and Q&A.
- Elias Jackson, Ph.D., director of scientific public relations for Vyripharm
- HJ Raza, M.D., Ph.D, chief medical officer of C3 Global Biosciences
- Andrew Serafini, CEO of C3 Global Biosciences
- Tracy Ryan, CEO of CannaKids.org
TMC Innovation Institute
2450 Holcombe Blvd., Suite X, Houston, TX 77021